On 12 December 2017, orphan designation (EU/3/17/1948) was granted by the European Commission to Premier Research Group Limited, United Kingdom, for 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (also known as Tempol) for the treatment of familial cerebral cavernous malformation.
The sponsorship was transferred to Premier Research Group S.L., Spain, in November 2019.
|Disease / condition||
Treatment of familial cerebral cavernous malformations
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.